Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals (VRTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of VRTX and the rest of the Medical group's stocks.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 894 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for VRTX's full-year earnings has moved 7.79% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, VRTX has returned 22.36% so far this year. At the same time, Medical stocks have lost an average of 4.25%. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, which includes 384 individual stocks and currently sits at #14 in the Zacks Industry Rank. On average, stocks in this group have gained 1.35% this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track VRTX. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals (VRTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of VRTX and the rest of the Medical group's stocks.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 894 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for VRTX's full-year earnings has moved 7.79% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, VRTX has returned 22.36% so far this year. At the same time, Medical stocks have lost an average of 4.25%. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, which includes 384 individual stocks and currently sits at #14 in the Zacks Industry Rank. On average, stocks in this group have gained 1.35% this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track VRTX. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VRTX - FREE